| Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ... European Psychiatry 54, 71-76, 2018 | 224 | 2018 |
| Pharmacological interventions for apathy in Alzheimer's disease MT Ruthirakuhan, N Herrmann, EH Abraham, S Chan, KL Lanctôt Cochrane Database of Systematic Reviews, 2018 | 133 | 2018 |
| Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease N Herrmann, M Ruthirakuhan, D Gallagher, NPLG Verhoeff, A Kiss, ... The American journal of geriatric psychiatry 27 (11), 1161-1173, 2019 | 126 | 2019 |
| Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review M Ruthirakuhan, AC Luedke, A Tam, A Goel, A Kurji, A Garcia Journal of aging research 2012 (1), 384875, 2012 | 126 | 2012 |
| Is it time to revise the diagnostic criteria for apathy in brain disorders P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ... The 2018 international consensus group. Eur Psychiatry 2018; 54: 71 76, 2018 | 110 | 2018 |
| Diagnostic criteria for apathy in neurocognitive disorders DS Miller, P Robert, L Ereshefsky, L Adler, D Bateman, J Cummings, ... Alzheimer's & Dementia 17 (12), 1892-1904, 2021 | 100 | 2021 |
| The roles of apathy and depression in predicting Alzheimer disease: a longitudinal analysis in older adults with mild cognitive impairment M Ruthirakuhan, N Herrmann, D Vieira, D Gallagher, KL Lanctôt The American Journal of Geriatric Psychiatry 27 (8), 873-882, 2019 | 92 | 2019 |
| Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial J Mintzer, KL Lanctôt, RW Scherer, PB Rosenberg, N Herrmann, ... JAMA neurology 78 (11), 1324-1332, 2021 | 77 | 2021 |
| Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease CS Liu, SA Chau, M Ruthirakuhan, KL Lanctôt, N Herrmann CNS drugs 29 (8), 615-623, 2015 | 73 | 2015 |
| A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease N Herrmann, J O'Regan, M Ruthirakuhan, A Kiss, G Eryavec, E Williams, ... Journal of the American Medical Directors Association 17 (2), 142-147, 2016 | 64 | 2016 |
| Latrepirdine for Alzheimer's disease S Chau, N Herrmann, MT Ruthirakuhan, JJ Chen, KL Lanctot Cochrane Database of Systematic Reviews, 2015 | 46 | 2015 |
| Three-dimensional quantitative imaging of telomeres in buccal cells identifies mild, moderate, and severe Alzheimer's disease patients S Mathur, A Glogowska, E McAvoy, C Righolt, J Rutherford, C Willing, ... Journal of Alzheimer's Disease 39 (1), 35-48, 2014 | 44 | 2014 |
| Natural and synthetic cannabinoids for agitation and aggression in Alzheimer's disease: a meta-analysis M Ruthirakuhan, KL Lanctôt, D Vieira, N Herrmann The Journal of clinical psychiatry 80 (2), 2246, 2019 | 40 | 2019 |
| Biomarkers of agitation and aggression in Alzheimer's disease: a systematic review M Ruthirakuhan, KL Lanctôt, M Di Scipio, M Ahmed, N Herrmann Alzheimer's & Dementia 14 (10), 1344-1376, 2018 | 38 | 2018 |
| Mild behavioral impairment is associated with progression to Alzheimer's disease: a clinicopathological study M Ruthirakuhan, Z Ismail, N Herrmann, D Gallagher, KL Lanctôt Alzheimer's & Dementia 18 (11), 2199-2208, 2022 | 37 | 2022 |
| Pregnancy and delivery outcomes following benzodiazepine exposure: a systematic review and meta-analysis S Grigoriadis, L Graves, M Peer, L Mamisashvili, M Ruthirakuhan, P Chan, ... The Canadian Journal of Psychiatry 65 (12), 821-834, 2020 | 36 | 2020 |
| Agitation, oxidative stress, and cytokines in Alzheimer disease: biomarker analyses from a clinical trial with nabilone for agitation M Ruthirakuhan, N Herrmann, AC Andreazza, NPLG Verhoeff, ... Journal of Geriatric Psychiatry and Neurology 33 (4), 175-184, 2020 | 36 | 2020 |
| Agitation and impulsivity in mid and late life as possible risk markers for incident dementia DR Bateman, S Gill, S Hu, ED Foster, MT Ruthirakuhan, AF Sellek, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 6 (1 …, 2020 | 34 | 2020 |
| Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease M Ruthirakuhan, N Herrmann, I Suridjan, EH Abraham, I Farber, ... Expert opinion on pharmacotherapy 17 (18), 2417-2429, 2016 | 32 | 2016 |
| Pharmacological management of agitation and aggression in Alzheimer’s disease: a review of current and novel treatments C S Liu, M Ruthirakuhan, S A Chau, N Herrmann, A F Carvalho, ... Current Alzheimer Research 13 (10), 1134-1144, 2016 | 32 | 2016 |
